Literature DB >> 12788799

Cardiovascular function in acromegaly.

R N Clayton1.   

Abstract

Even with modern treatment, acromegaly is associated with a 2- to 3-fold increase in mortality, mainly from vascular disease, which is probably a result of the long exposure of tissues to excess GH before diagnosis and treatment. There is accumulating evidence that effective treatment to lower serum GH levels to less than 1-2 ng/ml (glucose suppressed or random, respectively) and normalize IGF-I improves long-term outcome and survival. In addition to recognized cardiovascular risk factors of hypertension, type 2 diabetes mellitus, and dyslipidemia, there is accumulating evidence of specific structural and functional changes in the heart in acromegaly. Along with endothelial dysfunction, these changes may contribute to the increased mortality in this disease. There are specific structural changes in the myocardium with increased myocyte size and interstitial fibrosis of both ventricles. Left ventricular hypertrophy is common even in young patients with short duration of disease. Some of these structural changes can be reversed by effective treatment. Functionally, the main consequence of these changes is impaired left ventricular diastolic function, particularly when exercising, such that exercise tolerance is reduced. Diastolic function improves with treatment, but the effect on exercise tolerance is more variable, and more longitudinal data are required to assess the benefits. What scant data there are on rhythm changes suggest an increase in complex ventricular arrhythmias, possibly as a result of the disordered left ventricular architecture. The functional consequences of these changes are unclear, but they may provide a useful early marker for the ventricular remodeling that occurs in the acromegalic heart. Endothelial dysfunction, especially flow-mediated dilatation, is an early marker of atherosclerosis, and limited data imply that this is impaired in active acromegaly and can be improved with treatment. Similarly, early arterial structural changes, such as thickened intima media layer, appear more common in acromegalics, and there are hints that this may diminish with effective treatment, although more studies are required for a definite conclusion on this topic. In conclusion, impaired cardiac and endothelial structure and function in acromegaly are risk factors for vascular mortality and should be regarded as legitimate therapeutic targets in the overall management of this condition.

Entities:  

Mesh:

Year:  2003        PMID: 12788799     DOI: 10.1210/er.2003-0009

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  50 in total

Review 1.  Growth hormone and its disorders.

Authors:  J Ayuk; M C Sheppard
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

2.  Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Authors:  E Lin; T L Wexler; L Nachtigall; N Tritos; B Swearingen; L Hemphill; J Loeffler; B M K Biller; A Klibanski; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

3.  Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.

Authors:  R Helseth; S M Carlsen; J Bollerslev; J Svartberg; M Øksnes; S Skeie; S L Fougner
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

4.  Atrial conduction times and left atrium mechanical functions in patients with active acromegaly.

Authors:  A Ilter; A Kırış; Ş Kaplan; M Kutlu; M Şahin; C Erem; N Civan; F Kangül
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

5.  Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues.

Authors:  A Comunello; F Dassie; C Martini; E De Carlo; R Mioni; M Battocchio; A Paoletta; F Fallo; R Vettor; P Maffei
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

6.  Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance.

Authors:  F Bogazzi; M Lombardi; E Strata; G Aquaro; M Lombardi; C Urbani; V Di Bello; C Cosci; C Sardella; E Talini; E Martino
Journal:  J Endocrinol Invest       Date:  2010-02       Impact factor: 4.256

7.  Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.

Authors:  Marta Ragonese; Angela Alibrandi; Gianluca Di Bella; Ignazio Salamone; Soraya Puglisi; Oana Ruxandra Cotta; Maria Luisa Torre; Francesco Ferrau; Rosaria Maddalena Ruggeri; Francesco Trimarchi; Salvatore Cannavo
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

8.  Left ventricular synchronicity is impaired in patients with active acromegaly.

Authors:  Abdulkadir Kırış; Cihangir Erem; Oğuzhan Ekrem Turan; Nadim Civan; Gülhanım Kırış; Irfan Nuhoğlu; Abdulselam Ilter; Halil Onder Ersöz; Merih Kutlu
Journal:  Endocrine       Date:  2012-12-20       Impact factor: 3.633

Review 9.  Medical consequences of acromegaly: what are the effects of biochemical control?

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Mariano Galdiero; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.